


Journal Pre-proof

Temporal and structural patterns of extended-spectrum cephalosporin-resistant *Klebsiella pneumoniae* incidence in Swiss hospitals

L. Renggli, M. Gasser, C. Plüss-Suard, S. Harbarth, A. Kronenberg



PII: S0195-6701(21)00403-5

DOI: <https://doi.org/10.1016/j.jhin.2021.11.006>

Reference: YJHIN 6529

To appear in: *Journal of Hospital Infection*

Received Date: 10 September 2021

Revised Date: 4 November 2021

Accepted Date: 6 November 2021

Please cite this article as: Renggli L, Gasser M, Plüss-Suard C, Harbarth S, Kronenberg A, Temporal and structural patterns of extended-spectrum cephalosporin-resistant *Klebsiella pneumoniae* incidence in Swiss hospitals, *Journal of Hospital Infection*, <https://doi.org/10.1016/j.jhin.2021.11.006>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society.

Temporal and structural patterns of extended-spectrum cephalosporin-resistant *Klebsiella pneumoniae* incidence in Swiss hospitals

Renggli L^{*1}, Gasser M^{*1}, Plüss-Suard C¹, Harbarth S², Kronenberg A¹;

*contributed equally

¹ Swiss Centre for Antibiotic Resistance (ANRESIS), Institute for Infectious Diseases, University of Bern, Bern, Switzerland

² Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, WHO Collaborating Centre, Geneva, Switzerland

Summary

Background

Routine surveillance data revealed increasing rates of invasive extended-spectrum cephalosporin-resistant *Klebsiella pneumoniae* (ESCR-KP) in Switzerland, from 1.3% in 2004 to 8.5% in 2019 [1].

Aim

The main aim of this study was to understand the causes of this recent trend, specifically to identify predictors affecting the incidence of invasive ESCR-KP infections in Switzerland.

Methods

A retrospective observational multi-centre study was conducted in 21 Swiss hospitals over a period of 11 years (2009 – 2019). Potential predictor variables for the incidence of invasive ESCR-KP infections were studied with a multiple linear regression model. In an additional analysis, the overall ESCR-KP incidence (all sample sites) was investigated.

Findings

An increasing incidence of invasive ESCR-KP infections from 0.01 to 0.04 patients/1,000 bed-days was observed between 2009 and 2019 and confirmed by multiple linear regression analysis ($P < 0.01$). ESCR-KP incidence was higher in university hospitals ($P < 0.01$) and in the French-speaking region than in the German-speaking region ($P < 0.01$). There was no association with antibiotic consumption. Analysing the overall ESCR-KP incidence (all sample sites) revealed high variability between university hospitals, mainly due to a high proportion of patients with screening isolates at Geneva University Hospital (50% of patients with ESCR-KP).

Conclusion

The incidence of invasive ESCR-KP infections increased in Switzerland between 2009 and 2019 and was not associated with antibiotic consumption. Our findings indicate that in this low-incidence setting, structural factors such as the hospital type and the linguistic region play a more important role in relation to ESCR-KP incidence than the hospital's antibiotic consumption.

Introduction

Extended-spectrum cephalosporin-resistant *Klebsiella pneumoniae* (ESCR-KP) is a severe threat for hospitalized patients worldwide, causing bloodstream, intra-abdominal and urinary tract infections as well as severe pneumonia. In 2017, extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales were listed as one of the highest-priority pathogens for the research and development of new antibiotics by the World Health Organization [2]. ESCR-KP ranked third among the most prevalent antimicrobial-resistant bacteria in 2015, causing approximately 22.5 disability-adjusted life years (DALYs)/100,000 population in the European Union (EU) and European Economic Area (EEA) [3] and approximately 7 DALYs/100,000 population in Switzerland [4]. The percentage of invasive *K. pneumoniae* isolates with resistance to 3rd-generation cephalosporins increased in the EU and EEA from 21.5% to 31.7% (2009–2019) [5-7]. Routine surveillance data in Switzerland revealed an increase in the percentage of extended-spectrum cephalosporin resistance in invasive *K. pneumoniae* isolates from 4% to 8.5% (2009–2019) [1].

Previous work in Spain, the USA and China identified prior use of 3rd- and 4th-generation cephalosporins as one of the main risk factors for extended-spectrum cephalosporin resistance in *K. pneumoniae* [8-12]. Further risk factors that were described in the literature are prior use of fluoroquinolones, aminoglycosides [9, 13] and cotrimoxazole [14] since extended-spectrum cephalosporin resistance frequently accompanies cross-resistance to these antibiotics [15]. To date, it has not yet been investigated whether these factors are relevant in Switzerland, representing a low incidence setting.

The main aim of this study was to describe incidence rates of invasive ESCR-KP infections in Switzerland over time from 2009 to 2019 and to identify underlying predictors such as antibiotic consumption, hospital type (university vs. non-university) and linguistic region.

Overall ESCR-KP incidence (all sample sites) is of interest for infection control purposes especially since contact isolation is recommended for patients with ESCR-KP in Switzerland to prevent nosocomial spread [16] and for epidemiological understanding. An additional aim was therefore to analyse overall ESCR-KP incidence (all sample sites) in a separate model. By a comparison of this model with the main model based on invasive ESCR-KP infections only, it was then aimed to estimate a potential source of sampling bias.

Methods

Design and study population

A retrospective observational multi-centre study was conducted in 21 Swiss acute care hospitals over a period of 11 years (2009–2019). To homogenize the dataset, we restricted the analysis to hospitals with more than 200 beds and data availability for at least two years within the study period. Positive samples from patients, who were admitted to a hospital or attended an emergency department were included. Samples from patients attending the outpatient clinic only were excluded.

Data collection and processing

Antibiotic consumption and resistance data were obtained from the Swiss Centre for Antibiotic Resistance (ANRESIS) database. ANRESIS is a representative surveillance system that continuously collects national data on antibiotic use and antibiotic resistance [17].

Yearly antibiotic consumption was described in defined daily doses (DDD [18]) per 1,000 bed-days (BD) and reflects the amount of antibiotics delivered from the hospital pharmacy to individual departments. The consumption of 3rd- and 4th-generation cephalosporins, fluoroquinolones, trimethoprim/sulfamethoxazole, and aminoglycosides was aggregated at the hospital level.

ESCR-KP was defined as *K. pneumoniae* non-susceptible (resistant or intermediately susceptible) to at least one of all 3rd- or 4th-generation cephalosporins tested. Participating laboratories and hospitals are distributed all over Switzerland, laboratories are accredited by national authorities and use CLSI or EUCAST guidelines for antibiotic susceptibility testing. Deduplication was performed at the level of bacterial species by keeping only the most invasive isolate of all samples for a given year from the same patient. Incidence is given by the number of patients affected per 1,000 bed-days.

For invasive infections, only samples from sterile sites were considered. Screening samples were defined as samples that were labelled as such by the hospitals or as samples from faeces, anal swabs or intact skin. Isolates from non-screening sites (including invasive samples) were summarized as "clinical isolates". Clinical isolates were divided into three categories: isolates from patients who were screened as positive any time before a sample of a non-screening location was taken were described as "clinical isolate, patient previously screened positive". The remaining clinical isolates were categorized depending on their sample site as "clinical isolate, sterile site" and "clinical isolate, non-sterile site" (for details see supplementary data: Figure A1).

Statistical models

A multiple linear regression model was developed to identify predictor variables, which are potentially associated with the yearly incidence of invasive ESCR-KP infections (patients/1,000 BD). The following predictor variables were included in the initial model: yearly consumption of 3rd- and 4th-generation cephalosporins (DDD/1,000 BD), fluoroquinolones, trimethoprim/sulfamethoxazole or aminoglycosides; time (the year of isolate collection and antibiotic consumption, respectively); hospital type (university vs. non-university hospital); and linguistic region (German-, French- and Italian-speaking regions). The dependent variable (patients/1,000 BD) was transformed logarithmically to meet the assumptions for linear regression. The likelihood ratio test (chi-square statistics) was then used in a backwards elimination process ($P < 0.05$ to retain) to select the set of independent variables for the final model.

The German-speaking region was used as a reference in comparisons of the three-level factor linguistic region. To analyse differences between the French- and Italian-speaking regions, the French-speaking region was additionally used as a reference.

Additional analyses

An additional analysis was performed by studying the association of invasive ESCR-KP incidence with antibiotic consumption of the year before to consider the time lag between antibiotic use and resistance development. In another exploratory analysis, the overall ESCR-KP incidence (all sample sites), was investigated separately in an analogous model.

Results

On a national level, we observed an increase in the incidence of infections with invasive ESCR-KP from 0.01 to 0.04 patients/1,000 bed-days between 2009 and 2019 (Figure 1, Table A I). Incidences with invasive ESCR-KP infections were higher in university hospitals than in non-university hospitals (range of the yearly median 0.01-0.05 vs. 0.01-0.03 patients/1,000 bed-days) and in the French-speaking region than in the German-speaking region (range of the yearly median 0.01-0.05 vs. 0.01-0.04 patients/1,000 bed-days). These observations were confirmed by multiple linear regression analysis (each $P < 0.01$, Table I). No significant differences were found between the German- and Italian-speaking regions. There was no association observed between incidence of invasive ESCR-KP infections and antibiotic consumption of the same year nor with the consumption of the year before (data not shown).

An increase in ESCR-KP was also observed if all samples were considered (Figure 1, Table A II). The distribution of sample types is shown in Table A III. In this additional analysis with isolates from all sample sites (Table II) the predictor variables were mostly consistent with those of the model with clinical isolates from sterile sites. However, incidence was higher in French-speaking university hospitals compared to university hospitals in the German-speaking part (see interaction of the variables "University" and "French" in Table II) and thus, variability between university hospitals became larger (Figure 1, lower panel). The percentage of screening isolates was considerably higher in university compared to non-university hospitals (median 22% vs. 9%). In this dataset, the overall incidence at Geneva University Hospital was clearly the highest (0.49 patients per 1,000 bed-days). However, in 50% of all inpatients at Geneva University Hospital, ESCR-KP was detected in screening isolates only, and 15% were detected in clinical isolates from patients who were previously screened as positive (Figure 2).

Figure 1: Incidence of invasive ESCR-KP infections (*upper panels*) and overall ESCR-KP incidence (all sample sites, *lower panels*) in 21 Swiss hospitals (*points*), including Geneva University Hospital (*dashed line*). The median (*solid line*) and interquartile range (*shaded area*) of university hospitals (*blue*) and non-university hospitals (*green*) are compared.

Figure 2: Comparison of sample sites of patients with ESCR-KP in university hospitals (A to E), including Geneva University Hospital (A), and non-university hospitals (F to U) from 2009–2019.

Table I: Predictor variables of a model describing the incidence of invasive ESCR-KP infections [log(patients/1,000 BD)] in Switzerland from 2009 to 2019

Variable	Estimate ¹	95% CI	P value
Year	0.1	(0.07, 0.12)	< 0.001
University vs. non-university hospital	0.54	(0.35, 0.72)	< 0.001
French vs. German	0.4	(0.21, 0.59)	< 0.001
Italian vs. German	-0.06	(-0.35, 0.24)	0.7
3 rd - and 4 th -generation cephalosporins	no association*		
Fluoroquinolones	no association*		
Trimethoprim/sulfamethoxazole	no association*		
Aminoglycosides	no association*		
R ² /adjusted R ²	0.41/0.40		
F-statistic	26.89		< 0.001

* Variable does not improve the model (likelihood ratio chi-squared statistic, P> 0.05);

¹ a negative sign indicates a negative association

Table II: Predictor variables of a model describing overall ESCR-KP incidence (all sample sites) [log(patients/1,000 BD)] in Switzerland from 2009 to 2019

Variable	Estimate ¹	95% CI	P value
Year	0.16	(0.13, 0.18)	< 0.001
University vs. non-university hospital	0.70	(0.47, 0.92)	< 0.001
French vs. German	0.17	(-0.06, 0.4)	0.15
Italian vs. German	-0.18	(-0.44, 0.09)	0.19
University and French interaction	0.46	(0.08, 0.85)	0.02
3 rd - and 4 th -generation cephalosporins	no association*		
Fluoroquinolones	no association*		
Trimethoprim/sulfamethoxazole	no association*		
Aminoglycosides	no association*		
R ² /adjusted R ²	0.58/0.57		
F-statistic	55.82		< 0.001

* Variable does not improve the model (likelihood ratio chi-squared statistic, P> 0.05);

¹ a negative sign indicates a negative association

Discussion

Our study showed that the incidence of invasive ESCR-KP infections in Switzerland increased fourfold between 2009 and 2019. These findings are consistent with increasing extended-cephalosporin resistance rates of invasive *K. pneumoniae* in Switzerland over the last fifteen years and parallel the increasing resistance rates in other European countries [1, 5-7]. According to literature the spread of ESCR-KP may be affected by tourism to endemic regions and migration, nosocomial transmission, household transmission of discharged patients, increasing population densities and climate change [19-24].

The higher incidence of invasive ESCR-KP infections in university hospitals than in non-university hospitals may be caused by a higher risk for hospital-acquired infections in these environments [25] along with more severe and complex cases accommodated [26].

In the French-speaking region, the incidence of invasive ESCR-KP infections was higher than that in the German-speaking region. This finding may be partially explained by a high cross-border traffic of individuals including patients and medical staff from these regions to neighbouring countries with higher ESCR-KP prevalence levels (i.e. France, 2019 30.2%, Germany 12.2%) [6]. In contrast, a similar effect was not observed for the Italian-speaking region. ESCR-KP incidence rates in this area were not significantly higher than those in the German-speaking region despite an ESCR-KP rate of 57.6% in Italy (2019). However, data from the Italian-speaking part of Switzerland were sparse, as the area is relatively small and has only two hospitals with more than 200 beds.

There was no association found between the incidence of invasive ESCR-KP infections and the consumption of 3rd- and 4th-generation cephalosporins, fluoroquinolones, aminoglycosides or trimethoprim/sulfamethoxazole. On the one hand, these negative results are congruent with those of a local Swiss study, where no association between ESCR-KP and consumption of 3rd- and 4th-generation cephalosporins was found [27]. On the other hand, they are in contrast to the findings of several other studies that identified antibiotic consumption as a risk factor for the occurrence of ESCR-KP [8, 9, 12, 14, 23, 28, 29]. Reasons for these discrepancies with other studies may be the comparatively low incidence and low total antibiotic use in Switzerland [27, 30-33]. This presumption is supported by the result of the population-based mathematical modelling study of ESCR-KP of Kachalov et al., showing that the import of resistant pathogens was a key factor in low-prevalence countries (defined as an ESCR-KP resistance rate below 15%) compared to countries with medium prevalence where antibiotic consumption was the main driver of resistance [23]. Ecologic bias may be another explanation for these discrepancies, i.e. that data aggregation at the hospital level may not be sufficient to detect these correlations [34].

The approach of analysing overall ESCR-KP incidence, including isolates from all sample sites (which is frequently considered for infection control purposes), has led to additional important findings. Although the overall increase in ESCR-KP incidence was comparable, we noted highly variable incidence rates, especially among university hospitals. In our setting, this was mainly due to high total incidence rates observed in Geneva University Hospital, which is known for an extensive screening strategy, and therefore detecting unknown carriers more frequently. Screening activity at Geneva University Hospital was even substantially increased temporarily due to several clinical studies during the study period [35, 36]. Indeed, Geneva University Hospital had the highest percentage of patients with screening isolates (50%) and of clinical isolates from patients previously screened as positive (15%). Considering invasive isolates only made these differences disappear. This finding

indicates that different screening activities may bias overall ESCR-KP incidence even within a single country and that this has to be considered if data are compared between hospitals. This interpretation is in line with the results of a previous study that described heterogeneity in screening recommendations among different Swiss hospitals for multi-resistant bacteria [37]. It is important not to brand hospitals due to high resistance rates, which result from active screening policies, as early detection is important and may prevent nosocomial spread and thus additional costs. This is especially the case for microorganisms, where contact isolation is recommended, as is the case in Switzerland for patients with ESCR-KP [16].

This study has several limitations: (1) The data were aggregated at the hospital level and year. Inclusion of patient-specific data may essentially improve the models. With the use of data from electronic prescriptions, which are currently implemented in several Swiss hospitals, such an analysis will be possible in the future. (2) A separate analysis of nosocomial samples only was not possible due to incomplete labelling of these samples by the hospitals. Hence, it cannot be excluded that the data may also contain samples with community-acquired ESCR-KP. This circumstance might attenuate a potential association between inpatient antibiotic consumption and ESCR-KP incidence. (3) Not all screening samples were correctly labelled. However, including typical screening sample sites in our algorithm probably reduced this bias. (4) A further possible source of error was that not all laboratories sent the results of screening samples. Possible approaches to improve ESCR-KP surveillance include more rigorous labelling of screening samples, measuring the screening activity and nationwide implementation of screening guidelines.

The main strength of our study is the extensive data collection, covering 11 years and all university and tertiary hospitals in Switzerland. In addition, the analysis of Swiss data allowed stratification into different linguistic and socio-cultural regions due to the country's heterogeneity.

Conclusion

The incidence of invasive ESCR-KP infections increased in Switzerland between 2009 and 2019 and was not associated with antibiotic consumption. Our findings indicate that in this low-incidence setting, structural factors such as the hospital type and the linguistic region play a more important role in relation to ESCR-KP incidence than the hospital's antibiotic consumption. However, further analyses using patient-specific data are needed to investigate this relationship.

Acknowledgements

We acknowledge the input of Carolina Fankhauser-Rodriguez, who summarized the changing ESBL screening guidelines at Geneva University Hospital during the study period.

We thank all laboratories and hospitals providing data to the ANRESIS database.

References

1. Federal Office of Public Health and Federal Food Safety and Veterinary Office. Swiss Antibiotic Resistance Report 2020. Usage of Antibiotics and Occurrence of Antibiotic Resistance in Switzerland. November 2020. FOPH publication number: 2020-OEG-64.
2. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet Infectious Diseases*, 2018. 18: 318-327.
3. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *The Lancet Infectious Diseases*, 2019. 19: 56-66.
4. Gasser M, Zingg W, Cassini A and Kronenberg A. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in Switzerland. *The Lancet Infectious Diseases*, 2019. 19: 17-18.
5. European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2012.
6. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) Annual Epidemiological Report 2019. Stockholm: ECDC; 2020.
7. European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC;
8. Rice LB, Eckstein EC, DeVente J and Shlaes DM. Ceftazidime-resistant *Klebsiella pneumoniae* isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. *Clin Infect Dis*, 1996. 23: 118-24.
9. Asensio A, Oliver A, González-Diego P, Baquero F, Pérez-Díaz JC, Ros P, et al. Outbreak of a multiresistant *Klebsiella pneumoniae* strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. *Clin Infect Dis*, 2000. 30: 55-60.
10. Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, et al. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* bloodstream infection: risk factors and clinical outcome. *Intensive Care Med*, 2002. 28: 1718-23.
11. Lee SO, Lee ES, Park SY, Kim SY, Seo YH and Cho YK. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol*, 2004. 25: 832-837.
12. Deng J, Li YT, Shen X, Yu YW, Lin HL, Zhao QF, et al. Risk factors and molecular epidemiology of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in Xiamen, China. *J Glob Antimicrob Resist*, 2017. 11: 23-27.
13. Pessoa-Silva CL, Meurer Moreira B, Câmara Almeida V, Flannery B, Almeida Lins MC, Mello Sampaio JL, et al. Extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit: risk factors for infection and colonization. *J Hosp Infect*, 2003. 53: 198-206.
14. Lautenbach E, Patel JB, Bilker WB, Edelstein PH and Fishman NO. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *Clin Infect Dis*, 2001. 32: 1162-71.
15. Abayneh M, Tesfaw G and Abdissa A. Isolation of Extended-Spectrum beta-lactamase- (ESBL-) Producing *Escherichia coli* and *Klebsiella pneumoniae* from Patients with Community-Onset Urinary Tract Infections in Jimma University Specialized Hospital, Southwest Ethiopia. *Can J Infect Dis Med Microbiol*, 2018. 2018: 4846159.

16. Tissot F, Widmer AF, Kuster SP and Zanetti G. Enterobacteriaceae mit Breitspektrum Beta-Laktamasen (ESBL) im Spital: Neue Empfehlungen Swissnoso 2014. 2014.
17. ANRESIS. The Swiss Centre for Antibiotic Resistance, <https://www.anresis.ch/>; 2021 [accessed 3 August 2021].
18. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2021. Oslo, Norway 2020
19. Woerther PL, Andremont A and Kantele A. Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community level. *J Travel Med*, 2017. 24: S29-S34.
20. Nellums LB, Thompson H, Holmes A, Castro-Sánchez E, Otter JA, Norredam M, et al. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, 2018. 18: 796-811.
21. MacFadden DR, McGough SF, Fisman D, Santillana M and Brownstein JS. Antibiotic Resistance Increases with Local Temperature. *Nat Clim Chang*, 2018. 8: 510-514.
22. Riccio ME, Verschuuren T, Conzelmann N, Martak D, Meunier A, Salamanca E, et al. Household acquisition and transmission of extended-spectrum β -lactamase (ESBL) - producing Enterobacteriaceae after hospital discharge of ESBL-positive index patients. *Clin Microbiol Infect*, 2021 Epub ahead of print. PMID: 33421572.
23. Kachalov VN, Nguyen H, Balakrishna S, Salazar-Vizcaya L, Sommerstein R, Kuster SP, et al. Identifying the drivers of multidrug-resistant *Klebsiella pneumoniae* at a European level. *PLoS Comput Biol*, 2021. 17: e1008446.
24. Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, et al. Transmission dynamics of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. *Clin Infect Dis*, 2012. 55: 967-75.
25. Zingg W, Metsini A, Balmelli C, Neofytos D, Behnke M, Gardiol C, et al. National point prevalence survey on healthcare-associated infections in acute care hospitals, Switzerland, 2017. *Euro Surveill*, 2019. 24.
26. Kuster SP, Ruef C, Bollinger AK, Ledergerber B, Hintermann A, Deplazes C, et al. Correlation between case mix index and antibiotic use in hospitals. *J Antimicrob Chemother*, 2008. 62: 837-42.
27. Cusini A, Herren D, Butikofer L, Pluss-Suard C, Kronenberg A and Marschall J. Intra-hospital differences in antibiotic use correlate with antimicrobial resistance rate in *Escherichia coli* and *Klebsiella pneumoniae*: a retrospective observational study. *Antimicrob Resist Infect Control*, 2018. 7: 89.
28. Wiener J, Quinn JP and PA B. Multiple antibiotic-resistant *Klebsiella* and *Escherichia coli* in nursing homes. *JAMA*, 1999 281: 517-523.
29. Quan J, Zhao D, Liu L, Chen Y, Zhou J, Jiang Y, et al. High prevalence of ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in community-onset bloodstream infections in China. *J Antimicrob Chemother*, 2017. 72: 273-280.
30. The Center for Disease Dynamics EP. ResistanceMap: Antibiotic resistance. 2021.
31. ANRESIS. Resistance rates of a selection of highly resistant microorganisms in Switzerland, <https://www.anresis.ch/>; 2021 [accessed 6 April 2020].
32. Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra S, Pulcini C, et al. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. *The Lancet Infectious Diseases*, 2021. 21: 107-115.
33. European Centre for Disease Prevention and Control. Antimicrobial consumption in the EU/EEA – Annual Epidemiological Report 2019. Stockholm: ECDC; 2020.
34. Harbarth S, Harris AD, Carmeli Y and Samore MH. Parallel Analysis of Individual and Aggregated Data on Antibiotic Exposure and Resistance in Gram-Negative Bacilli. *Clinical Infectious Diseases*, 2001. 33: 1462-1468.
35. Pasricha J, Koessler T, Harbarth S, Schrenzel J, Camus V, Cohen G, et al. Carriage of extended-spectrum beta-lactamase-producing enterobacteriaceae among internal medicine patients in Switzerland. *Antimicrobial resistance and infection control*, 2013. 2: 20-20.

36. Maechler F, Schwab F, Hansen S, Fankhauser C, Harbarth S, Huttner BD, et al. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β -lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. *The Lancet Infectious Diseases*, 2020. 20: 575-584.
37. Martischang R, Buetti N, Balmelli C, Saam M, Widmer A and Harbarth S. Nation-wide survey of screening practices to detect carriers of multi-drug resistant organisms upon admission to Swiss healthcare institutions. *Antimicrobial resistance and infection control*, 2019. 8: 37-37.

Journal Pre-proof

Figures

Figure 1: Incidence of invasive ESCR-KP infections (*upper panels*) and overall ESCR-KP incidence (all sample sites, *lower panels*) in 21 Swiss hospitals (*points*), including Geneva University Hospital (*dashed line*). The median (*solid line*) and interquartile range (*shaded area*) of university hospitals (*blue*) and non-university hospitals (*green*) are compared.

Figure 2: Comparison of sample sites of patients with ESCR-KP in university hospitals (A to E), including Geneva University Hospital (A), and non-university hospitals (F to U) from 2009–2019.

Figure A1: Flowchart describing the definition of the three categories of clinical isolates and the screening isolates.

Tables

Table I: Predictor variables of a model describing the incidence of invasive ESCR-KP infections [$\log(\text{patients}/1,000 \text{ BD})$] in Switzerland from 2009 to 2019

Table II: Predictor variables of a model describing overall ESCR-KP incidence (all sample sites) [$\log(\text{patients}/1,000 \text{ BD})$] in Switzerland from 2009 to 2019

Table A I: Patients invasively infected with ESCR-KP per 1,000 bed-days in 2009 and 2019 overall and stratified by hospital type and linguistic region.

Table A II: All patients with ESCR-KP (including screening and clinical isolates) per 1,000 bed-days in 2009 and 2019 overall and stratified by hospital type and linguistic region.

Table A III: Sample characteristics

